Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Phase 3 Data Show RYBREVANT + LAZCLUZE Outperforms Osimertinib In Non-small
Johnson & Johnson announced that the MARIPOSA study showed RYBREVANT combined with LAZCLUZE provided consistent long-term benefits over osimertinib in advanced NSCLC patients with EGFR exon 19 deletions or L858R mutations, with 61% survival at three years compared to 53% for osimertinib.
Global Prostate Cancer Treatment Market Size - By Product
Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.
Ultrasound And Electrosurgical Energy Dissectors Market Projected Growth Outlined by
The ultrasound and electrosurgical energy dissectors market is projected to reach $8.48 billion by 2028 with a CAGR of 7.1%, driven by factors like point-of-care diagnostics, robotic surgeries, and outpatient procedures. Key players include Johnson & Johnson, Medtronic, and Olympus Corporation. Market segments include ultrasound and electrosurgical devices, applications in cardiology, gynecology, and general surgery, and end-users such as hospitals and ambulatory surgical centers.
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable ...
MARIPOSA study shows RYBREVANT® plus LAZCLUZE™ provides superior outcomes vs osimertinib in first-line EGFR-mutant NSCLC, with improved overall survival and CNS disease control.
Related Clinical Trials:
Mpox global outbreak leads to significant increases in pharmaceutical stock markets
The WHO's mpox declaration led to significant stock market increases for pharmaceutical, medical tech, and biopharmaceutical companies, while airline stocks declined, reflecting investor concerns about mpox's global spread.
Oral Thin Films Market Report Explores the Research, Outlook, Demand, Analysis 2024-2033
The oral thin films market is projected to reach $7.65 billion by 2028 with a CAGR of 13.6%, driven by specialty pharmaceuticals, precision medicine, and telemedicine. Key players include ZIM Laboratories, NAL Pharma, and Cure Pharmaceutical. The market is segmented by type, disease indication, and distribution channel.
Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Autolus Therapeutics' obe-cel, an autologous CAR-T cell therapy for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia, awaits FDA approval on November 16, 2024. The therapy targets CD-19 and has shown a 78% ORR in the FELIX study, with potential peak revenues of ~$300m. Despite a 25% share price drop, Autolus holds $700m in cash and has partnerships with BioNTech, Moderna, and Bristol Myers Squibb, positioning it for future growth.
J&J Submits Autoantibody-driven Disease Treatment for FDA Approval
Johnson & Johnson (J&J) has submitted nipocalimab, an FcRn blocker, for FDA approval for generalized myasthenia gravis, with potential to treat up to 10 disease indications, including rheumatoid arthritis.
Lykos CEO to depart after FDA rejection, layoffs
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.
Evernorth Will Offer a Private-Label Stelara Biosimilar in 2025
Evernorth Health Services will offer a private-label biosimilar of Stelara (ustekinumab) starting in early 2025, with a price over 80% lower than Stelara's list price. The biosimilar will be available for $0 out of pocket for eligible patients through Accredo, potentially saving individual patients around $4,000 per year. Evernorth has already seen strong interest in its private-label Humira biosimilar, with over 25% of eligible Accredo patients using it.
© Copyright 2025. All Rights Reserved by MedPath